Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
No biosimilar producers have made use of an accelerated US approval pathway introduced in 2010, and now the first case has found against a biosimilar for Enbrel. George Yu and Jason Harp explain where ...
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback